ResMed (RMD)
(Delayed Data from NYSE)
$218.57 USD
-1.40 (-0.64%)
Updated May 17, 2024 04:00 PM ET
After-Market: $218.56 -0.01 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RMD 218.57 -1.40(-0.64%)
Will RMD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RMD
Haemonetics' (HAE) Hospital & Plasma Segments, Innovation Aid
Maravai (MRVI) Advances in RNA Research With New Collaboration
RMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Haemonetics (HAE) Stock Up 10.9% YTD: Will the Rally Continue?
What Makes ResMed (RMD) a New Strong Buy Stock
Align Technology (ALGN) Gains From Innovation, Global Expansion
Other News for RMD
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today
Here are the biggest single-session post-results gains from the recent earnings season
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
MatrixCare Joins Health Gorilla’s Qualified Health Information Network (QHIN) to Enhance Patient Data Access
ResMed's MatrixCar partners with Health Gorilla